Abraxane, a new cancer drug designed to be less toxic than standard chemotherapy, did a better job of keeping cancer at bay in women whose breast cancer had spread, U.S. researchers said on Tuesday.
They said the Abraxane, made by Los Angeles-based Abraxis Bioscience Inc., kept cancer from progressing nearly twice as long as the Sanofi-Aventis cancer drug Taxotere, or docetaxel.
"It nearly doubled progression-free survival," said Dr. William Gradishar of Northwestern Memorial Hospital, whose study appears in the Journal of Clinical Oncology.
Abraxane is currently approved to treat breast cancer after other treatments have failed, but Gradasher said it may become more widely used as a first treatment for breast cancer that has spread.
& #8226; Read the full Reuters story.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Abraxane Approved for Use in China
- FDA Wants New Study From Abraxis
- Drug Data Boosts Abraxis Stock
- FDA to Consider Abraxis Request
- Abraxis Gets OK to Sell Abraxane In India
- Abraxis Loss Widens on Re-Acquisition Costs
- Abraxane Approved in Japan
- Biotech to Bet on Healthy Prognosis, Plans to Buy Back Shares